Tofacitinib Treatment Suppresses CD4+ T-Cell Activation and Th1 Response, Contributing to Protection against Staphylococcal Toxic Shock
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137456 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anders Jarneborn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Piperidines, Th1 Cells, Pyrimidines, Shock, Septic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Medical Research Council, Swedish state under the agreement between the Swedish Government and the county councils, National Natural science foundation of China.
Abstract (Originalsprache)
Staphylococcal toxic shock syndrome (STSS) is a rare, yet potentially fatal disease caused by Staphylococcus aureus (S. aureus) enterotoxins, known as superantigens, which trigger an intense immune response. Our previous study demonstrated the protective effect of tofacitinib against murine toxin-induced shock and a beneficial effect against S. aureus sepsis. In the current study, we examined the effects of tofacitinib on T-cell response in peripheral blood using a mouse model of enterotoxin-induced shock. Our data revealed that tofacitinib suppresses the activation of both CD4+ and CD8+ T cells in peripheral blood. Furthermore, both gene and protein levels of Th1 cytokines were downregulated by tofacitinib treatment in mice with enterotoxin-induced shock. Importantly, we demonstrated that CD4+ cells, but not CD8+ cells, are pathogenic in mice with enterotoxin-induced shock. In conclusion, our findings suggest that tofacitinib treatment suppresses CD4+ T-cell activation and Th1 response, thereby aiding in protection against staphylococcal toxic shock in mice. This insight may guide the future development of novel therapies for STSS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden.
- Department of Rheumatology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
ORCID-Profile: Anders Jarneborn, Zhicheng Hu, Meghshree Deshmukh, Pradeep Kumar Kopparapu, Tao Jin
Förderung
- Swedish Medical Research Council
- Swedish state under the agreement between the Swedish Government and the county councils
- National Natural science foundation of China
- Sahlgrenska University Hospitals Research Foundations
- Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning
- Swedish state under the agreement between the Swedish Government and the county councils, the ALF agreement
Zitieren
APA
Jarneborn, A., Hu, Z., Deshmukh, M., Kopparapu, P. K., & Jin, T. (2024). Tofacitinib Treatment Suppresses CD4+ T-Cell Activation and Th1 Response, Contributing to Protection against Staphylococcal Toxic Shock. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137456
Vancouver
Jarneborn A, Hu Z, Deshmukh M, Kopparapu PK, Jin T. Tofacitinib Treatment Suppresses CD4+ T-Cell Activation and Th1 Response, Contributing to Protection against Staphylococcal Toxic Shock. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137456
BibTeX
@article{Jarneborn2024,
author = {Jarneborn, Anders and Hu, Zhicheng and Deshmukh, Meghshree and Kopparapu, Pradeep Kumar and Jin, Tao},
title = {Tofacitinib Treatment Suppresses CD4+ T-Cell Activation and Th1 Response, Contributing to Protection against Staphylococcal Toxic Shock},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137456}
}
EUVIMED